Duvelisib, PI3K delta/gamma inhibitor (TBI4788)
$117.00 – $360.00
PI3K delta/gamma inhibitor
SKU | Stock | SIZE (mg) | Price | Quantity | ||
---|---|---|---|---|---|---|
TBI4788-5MG | Yes | 5 MG | $117.00 | |||
TBI4788-25MG | Yes | 25 MG | $360.00 |
- Description
- Terms
- Additional information
- Documents
- Reviews (0)
Description
Product Details
Formal Name: 8-Chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
Alternate Names: IPI-145
Molecular Formula: C22H17ClN6O
Formula Weight: 416.87
CAS Number: 1201438-56-3
Purity: >98%
Formulation: powder
Solubility: Soluble in DMSO (up to at least 25 mg/ml)
Storage: -20°C
Stability: ≥ 1 year.
Applications
PI3K delta/gamma inhibitor
Functions
Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor. It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor crosslinking activated pro-survival signals in primary chronic lymphocytic leukemia cells. Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, and others. Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells. Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes
Application Procedures
First dissolved in DMSO (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.
Additional information
SIZE (mg) | 25 MG, 5 MG |
---|
Be the first to review “Duvelisib, PI3K delta/gamma inhibitor (TBI4788)”
You must be logged in to post a review.
Reviews
There are no reviews yet.